Pharsight

Suboxone patents expiration

SUBOXONE's oppositions filed in EPO
SUBOXONE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855221 INDIVIOR INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2022

(1 year, 7 months ago)

US9931305 INDIVIOR INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Feb, 2022

(1 year, 7 months ago)

US10285910 INDIVIOR INC Sublingual and buccal film compositions
Oct, 2022

(11 months ago)

US8017150 INDIVIOR INC Polyethylene oxide-based films and drug delivery systems made therefrom
Feb, 2023

(7 months ago)

US8603514 INDIVIOR INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(6 months from now)

US11135216 INDIVIOR INC Sublingual and buccal film compositions
Aug, 2029

(5 years from now)

US9687454 INDIVIOR INC Sublingual and buccal film compositions
Aug, 2029

(5 years from now)

US8475832 INDIVIOR INC Sublingual and buccal film compositions
Mar, 2030

(6 years from now)

Suboxone is owned by Indivior Inc.

Suboxone contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.

Suboxone has a total of 8 drug patents out of which 4 drug patents have expired.

Expired drug patents of Suboxone are:

  • US9855221
  • US9931305
  • US10285910
  • US8017150

Suboxone was authorised for market use on 30 August, 2010.

Suboxone is available in film;buccal, sublingual dosage forms.

Suboxone can be used as treating opioid use disorder, treatment of opioid dependence/sublingual or buccal application, this drug is administered by sublingual route to humans for maintenance treatment of opioid dependence.

The generics of Suboxone are possible to be released after 26 March, 2030.

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 August, 2010

Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL, SUBLINGUAL

How can I launch a generic of SUBOXONE before it's drug patent expiration?
More Information on Dosage

SUBOXONE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic